Klotho Neurosciences, Inc. Warrant (KLTOW)

• 1 day: -2.07%
• 5 days: 85.62%
• 1 month: 47.92%
• 3 months: -26.99%
• 6 months: -29.00%
• Year to date: -43.31%
• 1 year: -33.18%
• 5 years: -79.71%
• 10 years: -79.71%
• Sector: Healthcare
• Industry: Biotechnology

About: Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Employees: 3

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

14% less funds holding

Funds holding: 22 [Q4 2024] → 19 (-3) [Q1 2025]

56% less capital invested

Capital invested by funds: $649K [Q4 2024] → $285K (-$364K) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5